The preprint titled "Discovery of GluA3 preferring AMPA receptor positive allosteric modulator BRD3290" announces the identification of a small molecule designated BRD3290, described in the title as a GluA3‑preferring AMPA receptor positive allosteric modulator. The title indicates that BRD3290 preferentially targets the GluA3 subunit of AMPA‑type ionotropic glutamate receptors and acts via positive allosteric modulation.
The available source excerpt contains the full manuscript title and author list but does not include the body of the abstract, methods, results, figures, tables, or conclusions. Therefore specific experimental data, assay formats, potency values, selectivity profiles, structure–activity relationships, or in vivo evaluations are not reported in the excerpt provided here.
The work is posted as a preprint on bioRxiv with DOI 10.64898/2026.07.26.740780. Authors are listed with affiliations to the Broad Institute of MIT and Harvard. Correspondence is listed to Sean P Moran (smoran@broadinstitute.org). The preprint is explicitly noted as not peer reviewed in the bioRxiv record.
Links in the bioRxiv entry point to a full PDF, supplementary material, and article history pages, but those materials were not included in the source excerpt used to produce this summary.
From the manuscript title alone, the molecular target is the AMPA receptor family, specifically the GluA3 subunit. The compound is characterized as a positive allosteric modulator, implying that it enhances receptor function via a binding site distinct from the orthosteric glutamate site. The preferential activity toward GluA3 is emphasized in the title, but the excerpt contains no experimental evidence, quantitative selectivity measures, or binding site characterization to substantiate the level or basis of that preference.
The opening line of the abstract (present in the excerpt) begins by naming schizophrenia as a debilitating neuropsychiatric disease, indicating the study may place discovery of BRD3290 in the context of therapeutic strategies for neuropsychiatric disorders. Beyond that first phrase, the abstract is truncated in the source provided, and no additional discussion of clinical rationale, intended therapeutic application, or translational experiments is available in the excerpt.
The bioRxiv entry notes the presence of a full PDF and supplementary materials linked from the article page. Readers seeking experimental methods, chemical structures, biochemical and electrophysiological data, pharmacokinetics, in vitro or in vivo efficacy, safety signals, or any structural biology supporting GluA3 preference should consult the full preprint and its supplementary files on bioRxiv. The DOI and article page provide access to those resources.
This summary is strictly limited to text and metadata present in the supplied source excerpt. Specific items not reported in the excerpt include, but are not limited to:
Because these critical details are not present in the excerpt, no further claims about the compound's therapeutic potential, safety, or detailed mechanism can be made here. All readers are advised to review the complete preprint and supplementary materials on bioRxiv for comprehensive information and to treat the findings as preliminary until peer review is completed.
The bioRxiv manuscript record (DOI 10.64898/2026.07.26.740780) includes links to the full PDF and supplementary materials. For correspondence or queries about the dataset and experimental details, the listed contact is Sean P Moran at the Broad Institute (smoran@broadinstitute.org).